Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to sharpen rejection detection in liver transplants

NCT ID NCT03193151

Knowledge-focused Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at liver transplant biopsy samples to better understand and predict organ rejection. Researchers will analyze gene activity in 300 biopsy samples from transplant patients to create a tool that can identify rejection types more accurately. Participants are those already receiving a biopsy as part of their standard care. The goal is to improve diagnosis, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2017

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study aims to recruit 300 biopsies from liver transplant patients for clinical indications and the standard of care biopsies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * biopsy for clinical indications Exclusion Criteria: * no consent, pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute

    COMPLETED

    Dallas, Texas, 75246, United States

  • Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital

    COMPLETED

    Camperdown, NSW 2050, Australia

  • Dep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego

    COMPLETED

    Katowice, 40-027, Poland

  • Division of Transplant Surgery, University of Washington

    COMPLETED

    Seattle, Washington, 98195, United States

  • Henry Ford Transplant Institute

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Independent Public Composite Regional Hospital

    COMPLETED

    Szczecin, 71-455, Poland

  • Institute for Liver Science, King's College London

    COMPLETED

    London, SE5 9NU, United Kingdom

  • Northwestern Memorial Hospital

    COMPLETED

    Chicago, Illinois, 60611, United States

  • Transplant Surgery, VCU Medical Center

    COMPLETED

    Richmond, Virginia, 23298, United States

  • University of Alberta, Laboratory Medicine and Pathology

    COMPLETED

    Edmonton, Alberta, T6G 2R7, Canada

  • University of California San Francisco, Transplant Research Unit

    COMPLETED

    San Francisco, California, 94143, United States

  • University of Maryland School of Medicine

    COMPLETED

    Baltimore, Maryland, 21201, United States

  • Vanderbilt University Medical Center, Vanderbilt Transplant Center

    WITHDRAWN

    Nashville, Tennessee, 37232, United States

  • Warsaw Medical University, Independent Public Clinical Hospital

    COMPLETED

    Warsaw, 02-097, Poland

  • Warsaw Medical University, Jesus the Child Clinical Hospital

    COMPLETED

    Warsaw, 02-005, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.